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A new dinuclear complex of formula [{Re(CO)3(py)}2(μ-4,4”-azobpy)](PF6)2, with 
py = pyridine and 4,4”-azobpy = 4,4”-azobis(2,2’-bipyridine), has been synthesized and 
characterized by spectroscopic and electrochemical techniques. The symmetrical nature of the 
dimetallic cation has been confirmed by nuclear magnetic resonance (NMR) measurements. When 
adding L-cysteine or L-glutathione, large and rapid changes in its UV-Vis absorption spectra were 
observed, which can be used for detecting both biologically relevant thiols. A promising activity 
for using this complex as a chemotherapeutic agent for bone cancer was also disclosed. Quantum 
mechanical calculations supported the experimental data.
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Introduction
Transition metal complexes with polypyridyl ligands 
containing the azo (−N=N−) group have been widely 
studied for diverse applications in bioinorganic chemistry, 
such as sensing of biologically relevant thiols,1 cell 
imaging,2 photodynamic therapy3 and chemotherapy.4 
In particular, tricarbonylrhenium(I) complexes with 
azobipyridines present synthetic versatility as well as 
thermal and photochemical stability, leading to their use 
as efficient probes for sensing or switching purposes. 
For example, we recently reported5 the preparation and 
properties of a symmetrical dinuclear complex of formula 
[(CH3CN)(CO)3Re(4,4”-azobpy)Re(CO)3(CH3CN)](PF6)2, 
with 4,4”-azobpy = 4,4”-azobis-(2,2’-bipyridine), which 
can be used for detecting L-cysteine (Cys) or as a molecular 
“switch” with a double proton-coupled electron transfer 
(PCET) process that occurs by adding a strong reductant 
such as dithionite. It must be emphasized that in this 
case the switching properties arise from an excited state 
centered on the reduced and protonated species derived 
from 4,4”-azobpy, contrasting to the switching properties 
exhibited by complexes previously studied by Otsuki et al.6 
based on excited states centered in auxiliary bpy ligands. A 
similar behavior as a “molecular switch” has been described 
in our recent work7 on the synthesis and properties of a 
mononuclear tetracyanoruthenium(II) complex coordinated 
to 4,4”-azobpy.
Taking into account that if we replace CH3CN as 
auxiliary ligands by less π-accepting ligands such as py 
(pyridine) would improve the sensibility of detection 
and/or depletion of biologically relevant thiols, we report 
herein the synthesis, electrochemical and spectroscopic 
characterization, interactions with Cys and L-glutathione 
(GSH) and activity against osteosarcoma cell lines 
of a new dinuclear symmetrical complex of formula 
[{Re(CO)3(py)}2(μ-4,4”-azobpy)](PF6)2 or (1)(PF6)2, whose 
structure is shown in Scheme 1.
Experimental
Materials and techniques
All chemicals used in this work were analytical-
reagent grade and used without further purification. 
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Re(CO)5Cl, Ag(CF3SO3) and GSH were purchased 
from Aldrich (St. Louis, MO, USA) and Cys from 
Fluka (München, Germany).  4,4”-Azobpy and 
[{Re(CO)3(Cl)}2(μ-4,4”-azobpy)] were synthesized as 
previously reported.5 CH3CN was freshly distilled over 
P4O10 for electrochemical measurements. Tetrakis(n-butyl)
ammonium-hexafluorophosphate (TBAH) was dried at 
150 °C for 24 h before being used as supporting electrolyte 
in electrochemical measurements. UV-Visible (UV-Vis) 
spectra were recorded on a Varian Cary 50 spectrophotometer, 
using 1-cm quartz cells. Infrared (IR) spectra were obtained 
as KBr pellets with a PerkinElmer Spectrum RX-I FTIR 
spectrometer. Cyclic voltammetry (CV) and differential 
pulse voltammetry (DPV) measurements were carried 
out in Ar-saturated solutions at a scan rate of 100 mV s−1 
by using a BAS Epsilon EC equipment, with vitreous C 
as working electrode, Pt wire as auxiliary electrode, and 
Ag/AgCl (3 M NaCl) as reference electrode. Nuclear 
magnetic resonance (NMR) spectra were obtained in CD3CN 
with a Bruker 300 MHz instrument operating at a frequency 
of 300.13 MHz for 1H NMR and 75.47 MHz for 13C NMR 
spectroscopy. Mass spectra (MS) were recorded at CIBION 
(Buenos Aires, Argentina) using a QTOF mass spectrometer 
from Waters Corporation (USA). Chemical analyses were 
carried out at INQUISUR (Bahía Blanca, Argentina) with an 
estimated error of ± 0.4%, using a CHN Elemental Analyzer 
CE-440 from Exeter Analytical (UK).
Computational procedures
Density functional theory (DFT) calculations were 
carried out with the Gaussian 03 program package.8 
Molecules were optimized using the PBE1PBE hybrid 
functional, which is composed of the Perdew, Burke and 
Ernzerhof exchange, and a correlation functional with 25% 
HF exchange.9 The basis set LanL2DZ was chosen for Re 
and 6-31G* for all other atoms. No symmetry restrictions 
were placed on the geometry optimizations. Frequency 
calculations were performed in all optimizations to ensure 
that these geometries corresponded to global minima. To 
include solvent polarization effects, all calculations were 
done by using the conductor-like polarizable continuum 
model (CPCM) with water as solvent. The contribution of 
different groups on the molecular orbitals were obtained 
using the GaussSum program, version 2.2.10
Cell line and growth conditions
Human osteosarcoma cell line (MG-63) was grown in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal bovine serum (FBS), 100 IU mL−1 penicillin and 
100 μg mL−1 streptomycin at 37 °C in 5% of CO2 atmosphere. 
This cell line was grown in a 75 cm2 flask until reaching 
70-80% of confluence. Then, the cells were subcultured using 
TrypLE TM. For experiments, cells were grown in multi-well 
plates. The number of cells were 20,000 cells well−1. DMEM 
and TrypLE TM were purchased from Gibco (Gaithersburg, 
MD, USA), and FBS was purchased from Internegocios 
(Buenos Aires, Argentina). After 24 h, the monolayers 
were washed with DMEM and incubated under different 
conditions according to the experiments. Tissue culture 
materials were purchased from Corning (Princeton, NJ, 
USA). Control experiments using the rhenium precursor and 
the bridging ligand could not be done due to their extreme 




tetrazolium bromide (MTT) assay was performed according 
to Mosmann.11 Briefly, cells were seeded in a 96-well 
dish, allowed to attach for 24 h, and treated with different 
concentrations of 1 and cisplatin at 37 °C for 24 h. A stock 
solution of the complex (20 mM in dimethyl sulfoxide 
(DMSO)) was prepared which was transferred in aliquots to 
the culture aqueous media up to a maximum concentration 
0.1 mM of 1 with no dissolution problems, thus confirming 
the hypothesis of its high solubility in water, stated in the 
Introduction section. Besides, cisplatin was dissolved 
using a 0.9% NaCl solution. Afterwards, the medium was 
changed and the cells were incubated with 0.5 mg mL−1 
MTT under normal culture conditions for 3 h. Cell viability 
was marked by the conversion of the tetrazolium salt MTT 
to a colored formazan by mitochondrial dehydrogenases. 
Color development was measured spectrophotometrically 
with a microplate reader (multiplate reader multiskan 
FC, Thermo Scientific) at λ = 570 nm after cell lysis in 
DMSO (100 μL per well). Cell viability was plotted as the 
percentage of the control value.
Scheme 1. Structure of complex 1.
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Statistical methods
At least three independent experiments were performed 
for each experimental condition. Results are expressed as 
percentage (%) of basal and represent the mean ± standard 
error of the mean (SEM). Statistical differences were 
analyzed using the Student’s test.
Preparation of [{Re(CO)3(py)}2(μ-4,4”-azobpy)](PF6)2·8H2O, 
(1)(PF6)2·8H2O
6 6  m g  ( 0 . 0 7 0  m m o l )  o f  t h e  p r e c u r s o r 
[{Re(CO)3Cl}2(4,4”-azobpy)], prepared as described 
before,5 36 mg (0.137 mmol) of Ag(CF3SO3) and 30 mL of 
a mixture of CH3OH:1,4-dioxane 1:2 (v/v) were placed in a 
50 mL round bottomed flask and refluxed for 3 h in the dark. 
One drop of pyridine was then added to the mixture and the 
reflux was kept for another 3 h. After cooling, the formed 
AgCl was filtered. The filtrate was evaporated to dryness, 
re-suspended in 1 mL of CH3OH, and precipitated with 
NH4PF6 (0.4 g in 2.5 mL of H2O). The mixture was kept at 
5 °C for 6 h and filtered. The orange solid was washed with 
cold H2O (3 × 10 mL) and diethyl ether (2 × 10 mL). The 
obtained orange solid was dried under vacuum over P4O10 for 
24 h. Yield: 60 mg (64.6%). Anal. for C36H40N8O14P2F12Re2, 
experimental (calcd.): C, 29.2 (29.4); H, 1.7 (2.7); N, 7.5 
(7.6); IR (KBr) ν / cm−1 2034, 1921, 1608, 1474, 1448, 841, 
558; 1H NMR (300.13 MHz, CD3CN) d 9.49 (d, 2H, J 5.9 Hz, 
Hi), 9.28 (d, 2H, J 5.9 Hz, Ha), 8.81 (d, 2H, J 2.0 Hz, Hg), 
8.55 (d, 2H, J 8.2 Hz, Hd), 8.35 (td, 2H, J 7.9, 1.5 Hz, Hc), 
8.30 (dd, 4H, J 6.6, 1.2 Hz, Hk), 8.14 (dd, 2H, J 6.0, 1.9 Hz, 
Hj), 7.87 (t, 4H, J 6.8 Hz, Hm), 7.32 (dd, 4H, J 7.6, 6.4 Hz, 
Hl); 13C NMR (75.47 MHz, CD3CN) d 159.5, 159.4, 157.1, 
156.1, 155.1, 153.0, 142.3, 140.9, 130.4, 127.7, 126.2, 120.6, 
119.4, 121.1; high-resolution MS (HRMS) m/z, calcd. for 
C36H24N8O6Re2 [M]2+: 518.0453, found: 518.0452; calcd. for 
[M + PF6]+: 1181.0535, found: 1181.0548.
Results and Discussion
Synthesis
For preparing the PF6− salt of 1, previously reported 
methods5,12,13 were followed, with slight modifications 
and no need of chromatographic separations. Introduction 
of py as an auxiliary ligand increases the solubility of 
the complex in aqueous solutions respect to that of the 
previously studied5 complex with CH3CN, a relevant 
property to be considered for applications in sensing of 
thiols and activity against osteosarcoma cells. Although 
single crystals for X-ray diffraction analysis of this complex 
could not be obtained, its purity was assessed by elemental 
CHN analyses, NMR spectra and HRMS measurements, 
as disclosed in the Experimental section.
UV-Vis spectrum
Figure 1 shows the UV-Vis absorption spectrum of 1 
in H2O. Exact positions of the bands were inferred from 
deconvolution procedures. The bands at λmax = 260 nm 
(molar absorptivity ε = 4.1 × 104 M−1 cm−1) and λmax = 280 nm 
(ε = 3.8 × 104 M−1 cm−1) can be assigned to intraligand (IL) 
transitions of the bridging ligand 4,4”-azobpy, as reported5 
before for the CH3CN analogue. The band at λmax = 337 nm 
(ε = 1.5 × 104 M−1 cm−1) can be assigned to a metal-ligand-
to-ligand charge transfer (MLLCT) dπ(Re) → 4,4”-azobpy 
transition that occurs from the HOMO (highest occupied 
molecular orbital) which is mainly localized on the metallic 
center (with a significant contribution from the carbonyl 
groups) to the LUMO + 1 (lowest occupied molecular 
orbital + 1) which has a major contribution of the bpy rings, 
as discussed in the analogous CH3CN complex.5 A second 
band at λmax = 412 nm (ε = 1.2 × 104 M−1 cm−1) can be 
observed and assigned to an MLLCT dπ(Re) → 4,4”-azobpy 
transition, from the HOMO to the LUMO, that has a major 
contribution from the azo group of the bridging ligand. 
These assignments are further supported by results of 
DFT calculations shown below. UV-Vis spectra do not 
change in CH3CN, as expected for tricarbonylrhenium(I) 
complexes.
IR spectrum
The IR spectrum of 1 is shown in Figure 2. The 
characteristic ν (C≡O) stretching frequencies of the 
tricarbonylrhenium(I) moieties are detected at 2034 
and 1921 cm−1 and can be assigned to A’(1) and A’(2) 
Figure 1. UV-Vis spectrum of 1 in H2O at room temperature.
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symmetries, respectively,5 in consistency with a facial 
configuration of the carbonyl ligands bonded to Re. The 
band of symmetry A” at 1936 cm−1 is barely seen as a 
shoulder of the band at 1921 cm−1 when the IR spectrum 
is amplified. The lower value observed for the stretching 
frequency of mode A’(1) in complex 1 vs. its analogue 
with CH3CN (ν(C≡O) = 2039 cm−1)5 indicates an increase in 
π-backbonding from ReI to the carbonyls in 1. The intense 
bands at 841 and 558 cm−1 correspond to the stretching 
and deformation modes of the P−F bonds of the anion 
PF6−, respectively. Due to the symmetrical structure of the 
complex, the −N=N− stretching band could not be observed.
NMR spectra
Figure 3 shows the 1H NMR spectrum of 1 in CD3CN, 
which confirms the identity and purity of the complex. 
A complete structure elucidation could be accomplished 
with the aid of two-dimensional NMR techniques such 
as correlation spectroscopy (COSY), 13C heteronuclear 
single quantum correlation (HSQC) and 13C heteronuclear 
multiple bond correlation (HMBC) (Figures S1 to S4, 
Supplementary Information (SI) section). Due to the 
symmetrical nature of the complex, the 1H NMR spectrum 
shows a set of 9 signals, which are assigned to the 
aromatic protons of 4,4”-azobpy and py. Since there 
are 10 non-equivalent protons, as shown in the inserted 
scheme in Figure 3, a set of 10 signals would be expected; 
however, the peak centered at d = 7.87 ppm integrates for 
four protons, indicating the overlapping of the signals of 
two protons from py with two protons from 4,4”-azobpy.
Electrochemistry
The redox potentials of 1 were determined by CV and 
DPV in CH3CN (0.1 M TBAH) at r.t. (room temperature) 
and referred vs. Ag/AgCl. Redox processes cannot be 
assigned to the solvent, as deduced from the baseline shown 
in Figure 4a. The scans were started at 0.2 V to avoid the 
break of the voltammograms near 0 V. As displayed in 
Figure 4b, six redox processes can be detected by both 
electrochemical techniques. In the oxidative region of 
the CV, the Re2+/+ redox couple exhibits a potential of 
E1/2 = 1.84 V, a value slightly lower than that observed for 
the CH3CN analogue.5 In the DPV, a small splitting (of 
70 mV) is observed for both Re2+/+ redox couples of 1 at 
E1/2 = 1.75 and 1.82 V, indicating a small delocalization 
in the corresponding mixed-valent species. In the 
reductive region, five additional waves can be observed 
by both techniques at E1/2 = −0.06, −0.38, −1.50, −1.76 
and −1.92 V, which are assigned to the redox processes 
azo0/−1, azo−1/−2, bpy0/−1, bpy−1/−2, bpy−2/−3, respectively, 
in agreement with previous assignments, supported by 
UV-Vis spectroelectrochemistry and DFT calculations for 
the reduced species, of the analogous species of formula 
[(CH3CN)(CO)3Re(4,4”-azobpy)Re(CO)3(CH3CN)]2+.5
Redox reactions with thiol-containing amino acids
Detection of biologically relevant amino acids with thiol 
Figure 2. IR spectrum (KBr pellet) of (1)(PF6)2.
Figure 3. 1H NMR spectrum of (1) (300.13 MHz, CD3CN) with their 
assignments.
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groups, such as Cys and GSH, is important considering 
that these molecules are involved in the control of cellular 
oxidative stress. For example, it has been observed that 
GSH is overexpressed in cancer cells, a fact that increases 
the tumor cell resistance to oxidative stress.3 Dirhenium 
tricarbonyl complexes with 4,4”-azobpy as a bridging 
ligand are interesting systems for Cys or GSH detection 
and/or cellular depletion, since the inclusion of two 
rhenium centers in the complex structure has a dramatic 
effect on the redox potentials of the azo couples; for 1, the 
first reductive wave in CV is detected at E1/2 = −0.06 V 
(vs. Ag/AgCl), while, for the similar bridged diruthenium 
species of formula [(bpy)2Ru(4,4”-azobpy)Ru(bpy)2]4+, the 
same process is detected at E1/2 = −0.59 V (vs. Ag/AgCl).6 
Comparison with rhenium monomers was not accomplished 
since they could not be obtained. This value is even 
higher than the first reductive wave for the dirhenium 
analogue of formula [(CH3CN)(CO)3Re(4,4”-azobpy)
Re(CO)3(CH3CN)]2+, with E1/2 = −0.12 V (vs. Ag/AgCl),5 
thus confirming that py is less π-accepting ligand than 
CH3CN, as mentioned in the Introduction section. A rapid 
reaction of 1 with Cys and GSH is therefore expected, as 
confirmed by following the changes of UV-Vis spectra with 
addition of both thiols, shown in Figure 5. The bands at 
λmax = 412 and 350 nm disappear, while new bands appear 
at λmax = 360 nm when both amino acids interact with 1, 
reactions which are completed within mixing time with a 
stoichiometric ratio of 2:1 [thiol]/[1], indicating a double 
reduction and double protonation of the azo (−N=N−) group 
to give an hydrazo (−HN−NH−) group in the bridging 
ligand. This assertion is supported by detection of the −NH 
proton signal at d = 7.07 ppm in the 1H NMR spectra of 
the reduced and protonated product (1H2) (Figure S5, SI 
section) and the disappearance of the two azo reduction 
couples in presence of a twofold excess of [L-Cys] over 
[1] (Figure S6, SI section). Selectivity was not tested in this 
study, although amino acids without thiol groups are not 
expected to react with 1. Calibration curves (Figure S7, SI 
section) for the thiol-containing amino acids studied here 
give detection limits in the micromolar range.
Figure 4. (a) Baseline voltammogram; (b) CV (blue curve) and DPV (red curve) of 1 in CH3CN, 0.1 M TBAH.
Figure 5. Addition of varying amounts of (a) Cys and (b) GSH to a solution of 1 in buffer Tris (pH = 7.54) at 25 °C.
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Effect of complex on cell viability
In order to test the effect on cell viability, human MG-63 
osteosarcoma cells were exposed to 1. Cisplatin was used 
as a clinical reference. Figure 6 shows that 1 impaired the 
cell viability in the range of 10-100 μM, with statistically 
significant differences versus basal condition (p < 0.01). 
The half maximal inhibitory concentration (IC50) value of 1 
is 19.5 ± 2.4 μM, suggesting a moderate anticancer activity 
of this complex as compared with other metal-based drugs 
reported for osteosarcoma treatment.14 It must be noted that 
several rhenium compounds showed similar IC50 values 
against cancer cells.15 In this case, no experimental evidence 
is presented to attribute the chemotherapeutic activity to the 
rapid reaction of the complex with GSH. However, there may 
be a link to these redox properties if we take into account 
the similar structure of 1 to the previously studied species4 
of formula [Re2(CO)6(dip)2L](PF6)2 (dip = 4,7-diphenyl-
1,10-phenanthroline; L = 4,4’-azopyridine), in which 
evidence has been obtained of chemotherapy via a 
mitochondria-to-cellular redox strategy and cell death via 
apoptosis. Besides, the chemotherapeutic activity could be 
related to the rapid reaction of 1 with GSH if we consider 
the role of this thiol in cancer progression.16 Our results 
point out that 1 is more active than cisplatin on MG-63 
cells (IC50 = 39 ± 1.8 μM).14
DFT calculations
Calculations at the DFT level were performed for 
species 1 and 1H2, with the purpose of having a better 
understanding of the nature of their molecular orbitals 
(MOs). As shown in Figure 7 and Tables S1 and S2 (SI 
section), there are considerable changes in the energy 
and composition of the frontiers MO’s between both 
complexes. In 1, Figure 8 (left) shows that the LUMO is 
mainly centered in the azo bridge with a similar contribution 
of the bpy rings. Upon reduction and protonation of 1 to 
form 1H2, the LUMO is mainly centered on the bpy rings, 
as shown in Figure 8 (right). The HOMO is almost the 
same for both complexes, having a major contribution of 
the metallic center and a minor one from the CO groups. 
The lowest energy UV-Vis bands in 1 and 1H2 can thus 
be assigned to MLLCT transitions, with a higher energy 
gap for 1H2 than that for 1, as indicated in Figure 7, in 
consistency with the difference observed experimentally 
between the UV-Vis absorption maxima of both species 
(see Figure 5).
Figure 6. Evaluation of the mitochondrial succinate dehydrogenase 
activity by the MTT assay in MG-63 cells in culture. Osteosarcoma 
cells were incubated with different doses of 1 for 24 h at 37 °C. After 
incubation, cell viability was determined by the MTT assay. Results are 
expressed as percentage (%) of basal and represent the mean ± SEM, 
n = 18. *Significant differences vs. control (p < 0.01).
Figure 7. MO energy diagrams (a) for complex 1 and (b) for the doubly reduced and protonated product 1H2.
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Conclusions
A new symmetrical dirhenium complex with 
4,4”-azobpy as a bridging ligand has been prepared and 
characterized by spectroscopic and electrochemical 
techniques. Detection of Cys or GSH at the micromolar 
level can be accomplished by measuring the fast and 
considerable UV-Vis absorption changes that occur upon 
double reduction and double protonation of the complex 
with both thiol containing amino acids, which can be 
rationalized by DFT calculations. This complex exhibits a 
remarkable activity against osteosarcoma cell lines.
Supplementary Information
Supplementary information (13C NMR spectrum, 
two-dimensional 1H-1H COSY spectrum, two-dimensional 
1H-13C HMBC spectrum, two-dimensional 1H-13C HSQC 
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in CD3CN; effect of chemical reduction on the cyclic 
voltammogramm of 1; calibration curves for Cys and GSH 
detection by reactions with 1; energies and compositions 
of MOs for 1 and 1H2) is available free of charge at 
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